PAREXEL Early Phase provides a wealth of expertise to add great value to your decision making process. As an established partner to the Biopharmaceutical industry, we knows the challenges you face. We anticipate obstacles and offer timely solutions. Our early phase specialists – expert scientists, clinical pharmacologists, experienced business leaders, and savvy project managers – have the therapeutic expertise, experience and resources to successfully navigate challenges and give our clients a competitive advantage that delivers them return on investment.
PAREXEL Early Phase has unparalleled In-house experience across a spectrum of therapeutic specialties. Key therapeutic areas of depth for our in-house early phase capabilities include:
Other areas of therapeutic expertise in early phase drug development include Infectious disease, allergy/immunology, oncology, dermatology and rheumatology. We also provide extensive reach of additional therapeutic expertise and access to patients via our dedicated Proof of Concept team. Accessing expertise from across PAREXEL, and using a broad, global network of investigator and academic sites, this dedicated team integrates expertise and capabilities in regulatory strategies, drug development, and clinical pharmacology and offers tailored solutions for clients Proof of Concept studies.
We are a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through our development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services.